Centene (CNC) Stock May Trade Below Fair Value As Illinois Medicaid Deal Lands
Centene stock has delivered a strong 119.3% return over the past year, yet its valuation checks still lean on the cheap side, which raises questions about how much of the recent optimism is already in the price.
- Over the last 12 months, Centene has returned 119.3%, which puts recent buyers in a very different position from investors who held through earlier, weaker years.
- Renewed momentum in Medicaid contracts in Illinois can support confidence in future cash flows, while the decision to exit Arkansas’ Medicaid expansion program highlights how changes in state funding and policy may affect the company’s earnings base.
- On Simply Wall St’s broader valuation checks, Centene screens as relatively cheap overall, with 5 out of 6 indicators pointing to undervaluation rather than an obvious premium.
The issue now is whether Centene’s recent rerating still leaves enough valuation upside to appeal to new investors at current levels.
Does Centene Look Undervalued on Sales?
The P/S ratio is a useful lens for Centene because revenue is a core yardstick for managed care groups where margins are often slim but scale matters. Centene trades on a P/S of 0.2x, compared with a Healthcare industry average of about 1.6x and a peer average of 1.8x, so the stock changes hands at a sizeable discount to the sector on each dollar of sales.
The fair P/S ratio implied by Simply Wall St’s model is 0.9x, which already factors in Centene’s size, typical margins and risk profile. Against that benchmark, the current 0.2x reading is well below what the model would usually expect for this kind of business. Despite the recent lift in sentiment after the Illinois Medicaid contract renewal, the market multiple still prices Centene as if its revenue stream deserves a wide discount to peers.
On balance, Centene stock appears undervalued on a P/S basis, with the market assigning a much lower multiple to its sales than either peers or the modelled fair range.
See what the numbers say about this price — find out in our valuation breakdown.
The Centene Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Centene's valuation puzzle leaves off by spelling out the specific assumptions about future growth, margins and earnings that would need to hold for the stock to be worth materially more or less than today’s price, and they sit on the company’s Community page. Instead of stopping at a single ratio or model output, they unpack the future that figure relies on so you can track over time whether those conditions still look realistic for Centene.
The community is split on Centene, with one camp leaning toward material upside and the other seeing the stock as close to fully priced.
Bull case: 20% undervalued
"Ongoing digital transformation and AI-driven payment integrity initiatives are set to deliver structural cost reductions and superior medical loss ratio management..."
Read the full Bull Case to see why Centene could be undervalued
Bear case: roughly fairly valued
"Influenza and influenza-like illnesses resulted in $130 million of unexpected medical expenses in Q1 2025 for Medicaid, highlighting potential volatility in medical costs..."
Read the full Bear Case to see why Centene could be overvalued
Do you think there's more to the story for Centene? Head over to our Community to see what others are saying!
The Bottom Line
Centene still screens as undervalued on market multiples, with the P/S discount suggesting investors are paying relatively little for each dollar of revenue compared with peers and the modelled fair range. The broader valuation checks look strong, which supports the idea that current pricing already bakes in a fair amount of caution. From here, the key question is whether Centene can sustain contract quality and cost control well enough for that discount to narrow, or whether ongoing policy and medical cost risks mean the current gap simply reflects the risk profile and remains in place.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com